Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H24Cl2N2O |
| Molecular Weight | 343.291 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | Assumed racemic |
SHOW SMILES / InChI
SMILES
CN(C)[C@H]1CCCC[C@@H]1N(C)C(=O)CC2=CC=C(Cl)C=C2Cl
InChI
InChIKey=FKUWIGXXBMULOI-HOTGVXAUSA-N
InChI=1S/C17H24Cl2N2O/c1-20(2)15-6-4-5-7-16(15)21(3)17(22)10-12-8-9-13(18)11-14(12)19/h8-9,11,15-16H,4-7,10H2,1-3H3/t15-,16-/m0/s1
| Molecular Formula | C17H24Cl2N2O |
| Molecular Weight | 343.291 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 05:36:19 GMT 2025
by
admin
on
Wed Apr 02 05:36:19 GMT 2025
|
| Record UNII |
C1X8MF00M5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-U-48800
Created by
admin on Wed Apr 02 05:36:19 GMT 2025 , Edited by admin on Wed Apr 02 05:36:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
137700072
Created by
admin on Wed Apr 02 05:36:19 GMT 2025 , Edited by admin on Wed Apr 02 05:36:19 GMT 2025
|
PRIMARY | |||
|
2370977-17-4
Created by
admin on Wed Apr 02 05:36:19 GMT 2025 , Edited by admin on Wed Apr 02 05:36:19 GMT 2025
|
PRIMARY | |||
|
C1X8MF00M5
Created by
admin on Wed Apr 02 05:36:19 GMT 2025 , Edited by admin on Wed Apr 02 05:36:19 GMT 2025
|
PRIMARY | |||
|
DTXSID901342694
Created by
admin on Wed Apr 02 05:36:19 GMT 2025 , Edited by admin on Wed Apr 02 05:36:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Has around 7.5-fold the potency of morphine in animal models.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
